Press Releases

04-05-2022	Pliant Therapeutics to Participate in Needham Healthcare Conference
02-28-2022	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
02-28-2022	Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers
02-24-2022	Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
02-24-2022	Pliant Therapeutics to Participate in Upcoming Investor Conferences
01-11-2022	Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones

Investors & Media